Over the past decade, several novel immunotherapies have transformed the treatment landscape of relapsed or refractory B-cell acute lymphoblastic leukaemia. In the pivotal TOWER trial, blinatumomab—a ...

More information: Eunice S. Wang et al, Ziftomenib in relapsed/refractory (R/R) NPM1 -mutant acute myeloid leukemia (AML): Phase 1b/2 clinical activity and safety results from the pivotal KOMET ...

Positive preliminary data from a phase 1 clinical trial was recently announced evaluating SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia ...

More information: Stefanie Weiss et al, Atovaquone and selinexor as a novel combination treatment option in acute myeloid leukemia, Cancer Letters (2025). DOI: 10.1016/j.canlet.2025.217501 ...

Key Takeaways Revuforj is approved for relapsed or refractory acute leukemia with KMT2A translocation in patients aged 1 year and older. The AUGMENT-101 trial showed a 21.2% complete remission rate ...

Histology Acute lymphoblastic leukemia (ALL) is a cancer of precursor B or T lymphoid cells. It is the most common cancer and leukemia in children. Adolescents, young adults, and older adults can also ...

Acute myeloid leukemia is further classified into subtypes. Most cancers and solid tumors are classified according to cell type, aggressiveness and propensity to spread to other organs.

A treatment called revumenib, which inhibits the protein menin, showed promising results for individuals with acute leukemia, and aided remission in 30% of study participants.

"Study unravels a cause of resistance to novel drug in patients with acute leukemia." ScienceDaily. ScienceDaily, 15 March 2023. <www.sciencedaily.com / releases / 2023 / 03 / 230315132419.htm>.

Diagnosis criteria: >80% of monocyte lineage cells should be monoblasts (hence the name “acute monoblastic leukemia”). AML M5b AML M5b accounts for 3-6% of AML and is seen in people of all ages.